Replies to post #35198 on Cytodyn Inc (CYDY)

[finesand]

gestalt - no doubts that middle and big pharma knows all about PRO 140 and Cytodyn. Sure they do, they are all professionals.

I also states quite the similar, our HIV-1 Monotherapy will threaten the very fabric of HAART treatment for BP.
BP could lose 30-50% of the market as our model shows - that is huge.

Maybe it is BP killing the stock for better negotiations, who knows (o8>

[tonysd57]

Gestalt:
And scare is definitely the operative word here. Our gang of four thinks along those lines realizing all of BP knows about Leronlimab and keeping a wary eye on progress. Combo is no real threat to bottom line of the few in HIV arena, Mono is the game changer and if they make us prove we have the cash, confidence and ability to take it to market, we might be sitting on this for another 14-18 months.

Then again, and right on cue, Gilead announced this morning they were writing off & taking $820 million impairment charge on anti-BCMA CART-T program for multiple myeloma.

'Kite will not be progressing in the development of Kite-585". Analysts think this could be a taste of things to come raising big questions over whether Gilead can hope to see anything close to $12 billion from the deal.

In need of a rescue-